8 results
8-K
KRTX
Karuna Therapeutics Inc
14 Mar 24
Other Events
7:26am
notifications with the Antitrust Division of the Department of Justice (the “Antitrust Division”) and the Federal Trade Commission (the “FTC”) pursuant … to the Hart-Scott-Rodino Antitrust Improvement Act of 1976 (the “HSR Act”) on January 9, 2024. On February 2, 2024, Bristol-Myers Squibb, in consultation
DEFM14A
KRTX
Karuna Therapeutics Inc
5 Feb 24
Proxy related to merger
4:12pm
Projections
Interests of Karuna’s Executive Officers and Directors in the Merger
Financing of the Merger
Antitrust Review Required for the Merger
Material … by the merger agreement that are payable by Bristol-Myers Squibb or Merger Sub in accordance with the terms of the merger agreement.
Antitrust Review Required
PREM14A
KRTX
Karuna Therapeutics Inc
22 Jan 24
Preliminary proxy related to merger
6:05am
in the Merger
Financing of the Merger
Antitrust Review Required for the Merger
Material U.S. Federal Income Tax Consequences of the Merger
Delisting … of the merger agreement.
Antitrust Review Required for the Merger (see page 59)
As further discussed in the section of this proxy statement entitled
DEFA14A
KRTX
Karuna Therapeutics Inc
22 Dec 23
Additional proxy soliciting materials
5:20pm
”) pending Karuna stockholder approval, required antitrust approvals, and customary closing conditions, for $330.00 per share in cash, reflecting a total … conditions, including approval of Karuna stockholders and receipt of required antitrust approvals.
What needs to be completed for the merger to close?
▪
DEFA14A
yv0s6et7
22 Dec 23
Additional proxy soliciting materials
5:20pm
8-K
EX-2.1
6a35 hpy6
22 Dec 23
Entry into a Material Definitive Agreement
5:07pm
- Prev
- 1
- Next